The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cell Cycle

• Publication date

  2009-08-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/cc.8.16.9355PMID 19625780
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.

  2012cited by this paper
• Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines

  2007cited by this paper
• The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases.

  2006cited by this paper
• Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.

  2006cited by this paper
• Clinical implications of FLT3 mutations in pediatric AML.

  2006cited by this paper
• Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C

  2006cited by this paper
• Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner

  2006cited by this paper
• Cell-cycle progression and response of germ cell tumors to cisplatin in vitro.

  2006cited by this paper
• Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.

  2006cited by this paper
• A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

  2005cited by this paper
• Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis.

  2004cited by this paper
• A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

  2004cited by this paper
• Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

  2004cited by this paper
• Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.

  2004cited by this paper
• Acute myeloid leukemia

  2004cited by this paper
• In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects.

  2004cited by this paper
• Internal Tandem Duplications of Flt3 Gene (Flt3/ITD) Predicts a Poor Post-Remission Outcome in Adult Patients with Acute Non-Promyelocytic Leukemia

  2004cited by this paper
• A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.

  2003cited by this paper
• An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

  2003cited by this paper
• Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

  2003cited by this paper
• SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

  2003cited by this paper
• CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

  2002cited by this paper
• FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.

  2002cited by this paper
• Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

  2002cited by this paper
• SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.

  2002cited by this paper
• Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

  2002cited by this paper
• PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model

  2002cited by this paper
• Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

  2002cited by this paper
• PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.

  2002cited by this paper
• Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

  2001cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells

  2000cited by this paper
• Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation

  2000cited by this paper
• Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

  2000cited by this paper
• Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.

  2000cited by this paper
• Acute myeloid leukemia.

  1999cited by this paper
• DNA cross-linker-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint function.

  1998cited by this paper
• Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines

  1997cited by this paper
• Cytotoxic effects of cell cycle phase specific agents: result of cell cycle perturbation.

  1990cited by this paper
• Improved retroviral vectors for gene transfer and expression.

  1989cited by this paper
• Improved Retroviral Vectors for Gene Transfer and Expression

  1989cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• Novel water-soluble and highly efficient dual type I/II next generation inhibitors of FMS-like tyrosine kinase 3 (FLT3).

  2025cites this paper
• Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: Novel molecular approaches and therapeutic challenges.

  2024cites this paper
• Identification of furo[2,3-d]pyrimidin-4-ylsulfanyl-1,3,4-thiadiazole derivatives as novel FLT3-ITD inhibitors.

  2024cites this paper
• Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated Acute Myeloid Leukemia (AML) to guide treatment strategy.

  2024cites this paper
• A review of FLT3 inhibitors in acute myeloid leukemia.

  2021cites this paper
• DDDT_A_274118 4439..4449

  2020cites this paper
• A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.

  2020cites this paper
• Development of UHPLC-MS/MS Method for Indirubin-3′-Oxime Derivative as a Novel FLT3 Inhibitor and Pharmacokinetic Study in Rats

  2020cites this paper
• Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia

  2020cites this paper
• LC-MS/MS Estimation of the Anti-Cancer Agent Tandutinib Levels in Human Liver Microsomes: Metabolic Stability Evaluation Assay

  2020cites this paper
• Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia

  2019cites this paper
• Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade.

  2019cites this paper
• FLT3 inhibitors in acute myeloid leukemia

  2018cites this paper
• Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia

  2017cites this paper
• Pharmacokinetic Interactions in Combination Therapies for Acute Myeloid Leukemia

  2016cites this paper
• DNA damage response and anti-apoptotic proteins expression in NPMc+ mutated cells in acute myeloid leukaemia

  2014cites this paper
• Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update

  2014cites this paper
• Attenuated Expression of Apoptosis Stimulating Protein of p53-2 (ASPP2) in Human Acute Leukemia Is Associated with Therapy Failure

  2013cites this paper
• FLT 3 Inhibitors for the Treatment of Acute Myeloid Leukemia

  2013cites this paper
• Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms

  2013cites this paper
• Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia

  2013cites this paper
• Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia

  2012cites this paper
• Diversity of the juxtamembrane and TKD1 mutations (Exons 13–15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data

  2012cites this paper
• Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways.

  2011cites this paper
• Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia

  2011cites this paper
• New Agents Targeting Angiogenesis in Glioblastoma

  2011cites this paper
• The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway

  2011cites this paper
• Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.

  2011cites this paper
• FLT3 inhibitors: a story of the old and the new

  2011cites this paper
• Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells

  2011cites this paper
• FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.

  2011cites this paper
• The clinical development of FLT3 inhibitors in acute myeloid leukemia

  2011cites this paper
• FLT3 inhibitors for the treatment of acute myeloid leukemia.

  2010cites this paper
• Molecular genetics in acute myeloid leukemia

  2010cites this paper
• Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: from bench to bedside

  2010cites this paper
• BRAF testing in advanced colorectal cancer: is it ready for prime time?

  2010cites this paper
• FLT 3 as a therapeutic target in AML : still challenging after all these years

  2010cites this paper
• FLT3 as a therapeutic target in AML: still challenging after all these years.

  2010cites this paper